MCRB Latest Press Releases

-- November 4, 2026 --

Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC) Globe Newswire 7:00 AM

-- November 3, 2026 --

Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients Globe Newswire 7:00 AM

-- October 15, 2026 --

Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026 Globe Newswire 7:00 AM

-- September 8, 2026 --

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 6:00 PM

-- September 1, 2026 --

Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference Globe Newswire 7:00 AM

-- August 5, 2026 --

Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs Globe Newswire 7:00 AM

-- July 8, 2026 --

Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment Globe Newswire 7:00 AM

-- June 25, 2026 --

Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres' SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes